Skip to main content

Beckman Coulter Posts 6-Percent Rise in Q3 Revenue as Profit Soars 31 Percent

NEW YORK (GenomeWeb News) — Beckman Coulter today said that third-quarter revenue increased 6.1 percent as profits jumped 31 percent.
 
Total receipts for the three months ended Sept. 30 increased to $631.2 million from $593.4 million year over year.
 
Beckman Coulter attributed the good numbers to increased revenues on consumables, particularly in Europe and, to a lesser extent, in the Far East.
 
R&D costs in the quarter increased 57 percent to $81 million year over year.
 
Net income for the quarter was up to $47.5 million, compared with $36.2 million during the same period last year.
 
Beckman Coulter said it had around $69.1 million in current cash and cash equivalents as of Sept. 30.
 
The company maintained it expects steady revenue growth of between 7 percent and 9 percent the fourth quarter of 2006, and for all of 2007.

The Scan

US Supports Patent Waivers

NPR reports that the Biden Administration has announced its support for waiving intellectual property protections for SARS-CoV-2 vaccines.

Vaccines Versus Variants

Two studies find the Pfizer-BioNTech SARS-CoV-2 vaccine to be effective against viral variants, and Moderna reports on booster shots to combat variants.

CRISPR for What Ails You

The Wall Street Journal writes that CRISPR-based therapies could someday be used to treat common conditions like heart attacks.

Nature Papers Review Integration of Single-Cell Assay Data, Present Approach to Detect Rare Variants

In Nature this week: review of ways to integrate data from single-cell assays, and more.